Nucelion Therapeutics, a Bharat Biotech subsidiary, has partnered with VeGen Bio to manufacture VL-2511, a dual-target CAR-T therapy for multiple myeloma. The collaboration will focus on technology transfer, manufacturing scale-up and cost optimisation to support wider access in India.
